Display options
Cite
Berg A, Gulati A, Ytre-Hauge S, et al. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget. 2017;8(40):68530-68541doi: 10.18632/oncotarget.19708.
Berg, A., Gulati, A., Ytre-Hauge, S., Fasmer, K. E., Mauland, K. K., Hoivik, E. A., Husby, J. A., Tangen, I. L., Trovik, J., Halle, M. K., Stefansson, I., Akslen, L. A., Woie, K., Bjørge, L., Salvesen, H. B., Salvesen, �. �. O., Werner, H. M. J., Haldorsen, I. S., & Krakstad, C. (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget, 8(40), 68530-68541. https://doi.org/10.18632/oncotarget.19708
Berg, Anna, et al. "Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers." Oncotarget vol. 8,40 (2017): 68530-68541. doi: https://doi.org/10.18632/oncotarget.19708
Berg A, Gulati A, Ytre-Hauge S, Fasmer KE, Mauland KK, Hoivik EA, Husby JA, Tangen IL, Trovik J, Halle MK, Stefansson I, Akslen LA, Woie K, Bjørge L, Salvesen HB, Salvesen ØO, Werner HMJ, Haldorsen IS, Krakstad C. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget. 2017 Jul 31;8(40):68530-68541. doi: 10.18632/oncotarget.19708. eCollection 2017 Sep 15. PMID: 28978135; PMCID: PMC5620275.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 31;8(40):68530-68541. doi: 10.18632/oncotarget.19708. eCollection 2017 Sep 15.

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.

Oncotarget

Anna Berg, Ankush Gulati, Sigmund Ytre-Hauge, Kristine E Fasmer, Karen K Mauland, Erling A Hoivik, Jenny A Husby, Ingvild L Tangen, Jone Trovik, Mari K Halle, Ingunn Stefansson, Lars A Akslen, Kathrine Woie, Line Bjørge, Helga B Salvesen, Øyvind O Salvesen, Henrica M J Werner, Ingfrid S Haldorsen, Camilla Krakstad

Affiliations

  1. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
  2. Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.
  3. Department of Radiology, Haukeland University Hospital, Bergen, Norway.
  4. Section of Radiology, Department of Clinical Medicine, University of Bergen, Norway.
  5. Department of Pathology, Haukeland University Hospital, Bergen, Norway.
  6. Department of Clinical Medicine, Centre for Cancer Biomarkers, Bergen, Norway.
  7. Unit for Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

PMID: 28978135 PMCID: PMC5620275 DOI: 10.18632/oncotarget.19708

Abstract

PURPOSE: Distinguishing complex atypical hyperplasia (CAH) from grade 1 endometrioid endometrial cancer (EECG1) preoperatively may be valuable in order to prevent surgical overtreatment, particularly in patients wishing preserved fertility or in patients carrying increased risk of perioperative complications.

MATERIAL AND METHODS: Preoperative histological diagnosis and radiological findings were compared to final histological diagnosis in patients diagnosed with CAH and EECG1. Imaging characteristics at preoperative magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computer tomography (FDG-PET/CT) were compared with tumor DNA oligonucleotide microarray data, immunohistochemistry findings and clinicopathological annotations.

RESULTS: MRI assessed tumor volume was higher in EECG1 than in CAH (p=0.004) whereas tumor apparent diffusion coefficient value was lower in EECG1 (p=0.005). EECG1 exhibited increased metabolism with higher maximum and mean standard uptake values (SUV) than CAH (p≤0.002). Unsupervised clustering of EECG1 and CAH revealed differentially expressed genes within the clusters, and identified PDZ-binding kinase (PBK) as a potential marker for selecting endometrial lesions with less aggressive biological behavior.

CONCLUSION: Both PBK expression and preoperative imaging yield promising biomarkers that may aid in the differentiation between EECG1 and CAH preoperatively, and these markers should be further explored in larger patient series.

Keywords: FDG-PET/CT; MRI; PBK; endometrial carcinoma; endometrial hyperplasia

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

References

  1. Eur Radiol. 2013 Oct;23 (10 ):2916-25 - PubMed
  2. Clin Radiol. 2012 Jan;67(1):2-12 - PubMed
  3. Oncotarget. 2015 Jan 20;6(2):1327-39 - PubMed
  4. Gynecol Oncol. 2015 Nov;139(2):261-7 - PubMed
  5. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 - PubMed
  6. Cancer. 2005 Jun 1;103(11):2304-12 - PubMed
  7. Gynecol Oncol. 2014 Mar;132(3):669-76 - PubMed
  8. Acta Obstet Gynecol Scand. 2009;88(11):1234-42 - PubMed
  9. Gynecol Oncol. 2012 Apr;125(1):124-8 - PubMed
  10. Acta Obstet Gynecol Scand. 2013 May;92 (5):536-45 - PubMed
  11. Oncotarget. 2016 Apr 19;7(16):21454-68 - PubMed
  12. Cancer. 1985 Jul 15;56(2):403-12 - PubMed
  13. Theranostics. 2013 Oct 07;3(10):787-801 - PubMed
  14. Cancer. 2006 Feb 15;106(4):804-11 - PubMed
  15. J Natl Cancer Inst. 2010 May 5;102(9):605-13 - PubMed
  16. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12 ):4834-9 - PubMed
  17. J Nucl Med. 2015 Aug;56(8):1191-8 - PubMed
  18. Oncogene. 2012 May 10;31(19):2389-400 - PubMed
  19. Gynecol Oncol. 2010 Dec;119(3):516-9 - PubMed
  20. Cancer. 2006 Feb 15;106(4):812-9 - PubMed
  21. Obstet Gynecol. 2013 Jun;121(6):1172-80 - PubMed
  22. J Clin Oncol. 2010 Feb 10;28(5):788-92 - PubMed
  23. Mol Cancer. 2015 Jun 17;14:121 - PubMed
  24. Int J Clin Exp Pathol. 2014 Oct 15;7(11):8059-64 - PubMed
  25. Cancer Res. 2012 Jun 15;72(12):3060-8 - PubMed
  26. Oncogene. 2007 Mar 22;26(13):1971-82 - PubMed
  27. Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9 - PubMed
  28. BMC Cancer. 2013 Apr 02;13:175 - PubMed
  29. Gynecol Oncol. 2015 Nov;139(2):369-76 - PubMed
  30. BJOG. 2014 Mar;121(4):477-86 - PubMed
  31. Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7 - PubMed
  32. Oncotarget. 2015 Jun 20;6(17):15594-609 - PubMed
  33. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10781-6 - PubMed
  34. Obstet Gynecol. 2012 Nov;120(5):1160-75 - PubMed
  35. Int J Clin Exp Pathol. 2015 Nov 01;8(11):15467-73 - PubMed

Publication Types